Seeking Alpha

Actavis plc. (ACT)

  • Jan. 25, 2012, 1:46 PM
    Watson Pharmaceuticals (WPI +2.8%) gets a lift from a Morgan Stanley upgrade to Overweight, noting that potential earnings upside and a higher valuation could drive the shares up 16% or more.
    | Comment!
  • Jan. 24, 2012, 11:24 AM
    Canaccord Genuity weighs in on Columbia Laboratories (CBRX +2.2%) after the firm was rocked by a FDA rejection of its preterm birth prevention gel. Though analyst Randall Stanicky acknowledges the "disappointment," he still sees potential for CBRX and rival Watson Pharmaceuticals (WPI -3.4%) on possible M&A activity and the under-leveraged balance sheets the firms carry.
    | Comment!
  • Jan. 24, 2012, 6:48 AM
    Watson Pharmaceuticals (WPI) announces prelim FY11 EPS of $4.75-4.77 vs. $4.61 consensus, and FY11 revenue of $4.57B vs. $4.53B consensus. For FY12, the company sees EPS of $5.25-5.55 and revenue of $5.3B. (PR) (earlier)
    | Comment!
  • Jan. 24, 2012, 2:27 AM
    Watson Pharmaceuticals (WPI) agrees to buy Ascent Pharmahealth for A$375M ($396M), turning Watson into the fifth-largest generic pharmaceuticals firm in Australia and the largest in Singapore, while giving the company footholds in Malaysia, Hong Kong, Vietnam and Thailand. The deal will be immediately accretive to 2012 earnings.
    | Comment!
  • Jan. 23, 2012, 8:17 AM
    Columbia Labs (CBRX) -52.5% premarket after trading was suspended all day Friday following the FDA's negative vote on the company's Prochieve drug candidate. Partner Watson Pharmaceutials (WPI) is little changed after falling 3.5% on Friday. Rival K-V (KV.A) +1.9% after Friday's 9.3% gain.
    | Comment!
  • Jan. 17, 2012, 2:08 PM
    Shares of K-V Pharmaceutical (KV.A +16.9%) soar after rival Columbia Laboratories' preterm birth gel is deemed "not effective" by the FDA. Also showing some action related to the news is Watson Pharmaceuticals (WPI -2.6%).
    | Comment!
  • Jan. 6, 2012, 10:39 AM
    Sabrient Systems reveals its “Baker’s Dozen” list of 13 stocks to buy and hold through the calendar year: STX, WNR, OCN, WPI, UTHR, CLD, GSM, DAN, AGCO, DXPE, KRO, URI, ASCA. Sabrient's lists have easily outperformed the S&P in each of the past three years.
    | Comment!
  • Dec. 27, 2011, 2:54 PM
    Reuters' John Wasik identifies health care as a sector that will grow in 2012 on the strength of a long-term demographic trend that is pushing up demand for medical services, devices, and pharmaceuticals. He argues that while big pharma ETFs could see a gain, a focus on generic pharmaceutical names looks to be an even better bet as governments and companies look to cut costs. Big pharma ETFs: XPH, IHE, PJP, PPH, DRGS. Generic pharma firms: IPXL, MYL, PRX, TEVA, WPI, PRGO.
    | Comment!
  • Dec. 19, 2011, 4:36 PM
    Amgen (AMGN) and Watson Pharmaceuticals (WPI) will collaborate to develop and market several oncology antibody biosimilar medicines. Under the terms of the agreement, Amgen will assume primary responsibility for development and manufacturing, while Watson will contribute up to $400M in co-development costs, provide development support and will share product development risks.
    | Comment!
  • Dec. 2, 2011, 8:59 AM
    More on the Lipitor fallout: Though Watson Pharmaceuticals (WPI) took a hit after Ranbaxy Laboratories landed FDA approval to sell a generic copy of Lipitor, the firm received some good news when health insurer WellPoint (WLP) announced it would favor WPI's drug version with a $10-$15 co-payment over Pfizer's (PFE) brand name. Watson should also see a major boost with Wal-Mart's (WMT) announcement it will sell its version of Lipitor.
    | 1 Comment
  • Nov. 30, 2011, 4:02 PM
    The Lipitor war gets hotter for Watson Pharmaceuticals (WPI -4.3%) just hours after confirming its generic launch, as reports surface that Indian drug maker Ranbaxy Laboratories is poised to receive its own approval from the FDA to launch its generic version of the drug.
    | Comment!
  • Nov. 30, 2011, 8:07 AM
    Lipitor Wars (previous): Watson Pharmaceuticals (WPI) confirms it launched an authorized generic version of Lipitor under an exclusive agreement with Pfizer (PFE) that it calls the "largest generic product launch in U.S. history." Pfizer - for its part - says it has reached deals with drugstore chains and PBMs to offer its branded version at sharply reduced prices and is reaching out to consumers with its website to entice consumers with a discount card.
    | Comment!
  • Nov. 30, 2011, 5:35 AM
    The patent on Pfizer's (PFE) Lipitor, which has generated over $130B in sales, ends today, although the company is hoping it can hold onto a third of the 3M Americans who take it. At the moment, only Watson (WPI) will be able to sell a generic version in the U.S., but after 6 months, any firm will be able to.
    | 1 Comment
  • Nov. 29, 2011, 2:06 PM
    Watson Pharmaceuticals (WPI +2%) gains on FDA approval of its generic version of Bayer's (BAYRY.PK +0.7%) Yaz birth-control pill, adding to the company's growing number of products for women's health.
    | Comment!
  • Nov. 10, 2011, 11:36 AM
    Shares of Watson Pharmaceuticals (WPI -0.1%) and Teva Pharmaceuticals (TEVA -1.5%) could see volatility with a breaking Bloomberg report indicating that a court has approved Watson to sell a generic version of Seasonique - denying Teva's bid to stop the firm from selling the oral contraceptive.
    | Comment!
  • Nov. 1, 2011, 7:26 AM
    Watson Pharmaceuticals (WPI): Q3 EPS of $1.09 beats by $0.04. Revenue of $1.08B (+% Y/Y) misses by $10M. (PR)
    | Comment!
Visit Seeking Alpha's
ACT vs. ETF Alternatives
Company Description
Actavis PLC specialty pharmaceutical company engaged in developing, manufacturing and distributing generic, brand and biosimilar products.
Sector: Healthcare
Industry: Drugs - Generic
Country: United States